These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22681723)

  • 1. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.
    Tariot P; Salloway S; Yardley J; Mackell J; Moline M
    BMC Res Notes; 2012 Jun; 5():283. PubMed ID: 22681723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
    Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
    Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.
    Farlow M; Veloso F; Moline M; Yardley J; Brand-Schieber E; Bibbiani F; Zou H; Hsu T; Satlin A
    BMC Neurol; 2011 May; 11():57. PubMed ID: 21612646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
    Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
    Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
    Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
    Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities.
    Rosenblatt A; Gao J; Mackell J; Richardson S
    Am J Alzheimers Dis Other Demen; 2010 Sep; 25(6):483-9. PubMed ID: 20558849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
    Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
    Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
    Homma A; Atarashi H; Kubota N; Nakai K; Takase T
    J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Ohbayashi T
    Dement Geriatr Cogn Disord; 2008; 25(5):399-407. PubMed ID: 18391486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
    Salloway S; Mintzer J; Cummings JL; Geldmacher D; Sun Y; Yardley J; Mackell J
    Am J Alzheimers Dis Other Demen; 2012 Sep; 27(6):421-32. PubMed ID: 22930699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
    Matthews HP; Korbey J; Wilkinson DG; Rowden J
    Int J Geriatr Psychiatry; 2000 Aug; 15(8):713-20. PubMed ID: 10960883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.
    Doody RS; Geldmacher DS; Gordon B; Perdomo CA; Pratt RD;
    Arch Neurol; 2001 Mar; 58(3):427-33. PubMed ID: 11255446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
    Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
    Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
    Doody RS; Ferris S; Salloway S; Yijun Sun ; Goldman R; Yikang Xu ; Gao J; Murthy AK
    Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):155-9. PubMed ID: 19949165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
    Doody RS; Geldmacher DS; Farlow MR; Sun Y; Moline M; Mackell J
    Dement Geriatr Cogn Disord; 2012; 33(2-3):164-73. PubMed ID: 22572767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
    Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.
    Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown RG; Banerjee S; Adams J; Johnson T; Bentham P; Phillips PP
    Lancet Neurol; 2015 Dec; 14(12):1171-81. PubMed ID: 26515660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.